ESCRS 2023: Thomas Bosshard discusses Oertli's 3-platform approach

News
Video

At this year's ESCRS meeting, we visited the Oertli Instruments booth, where co-CEO and co-owner Thomas Bosshard highlighted the company's 3-platform approach.

At this year's European Society of Cataract and Refractive Surgeons (ESCRS) meeting in Vienna, Austria, we visited the Oertli Instruments booth, where co-CEO and co-owner Thomas Bosshard highlighted the company's 3-platform approach. Here's our conversation, live from the congress floor.

Editor's note: This transcript has been edited for clarity.

Thomas Bosshard: Hey guys my name is Thomas, Thomas Bosshard. I'm the co-owner and CO-CEO of Oertli Instruments in Switzerland. We are proud to bring to the ESCRS, of course, our 3-platform strategy with the OS4, the CataRhex 3 and the Faros, which are highly renowned for super dynamic cataract surgery and vitrectomy surgery. With all its features, peripheral products and of course, along with it, our highly dynamic team, which is here for our customers and partners.

Probably the most interesting thing which we are currently featuring and getting more and more wild and exciting about is our Speed Mode with our with our CataRhex 3 and all our other platforms, which is a highly effective tool for safer and simpler surgery, whether it's in cataract or vitrectomy procedures.

In 2024, you should be excited about quite great pipeline which we are about to start early over the next few years which is to come. It's going to be a very interesting time from 2024 on, at and around Oertli Instruments.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
© 2025 MJH Life Sciences

All rights reserved.